SRTS250117P8000
- 0.65
- 0.000.00%
Sensus Healthcare Newsroom
H.C. Wainwright Maintains Sensus Healthcare(SRTS.US) With Buy Rating, Raises Target Price to $11
Sensus Healthcare Is Maintained at Buy by HC Wainwright & Co.
Sensus Healthcare Analyst Ratings
Maxim Group Maintains Sensus Healthcare(SRTS.US) With Buy Rating, Raises Target Price to $14
Roth MKM Maintains Sensus Healthcare(SRTS.US) With Buy Rating, Maintains Target Price $10
Roth MKM Keeps Their Buy Rating on Sensus Healthcare (SRTS)
Sensus Healthcare Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Sensus Healthcare, Maintains $10 Price Target
Roth MKM Remains a Buy on Sensus Healthcare (SRTS)
Sensus Healthcare Analyst Ratings
HC Wainwright & Co. Maintains Buy on Sensus Healthcare, Raises Price Target to $10
Maxim Group: Maintains Sensus Healthcare (SRTS.US) rating, adjusted from buy to buy rating, and adjusted target price from $7.00 to $10.00.
Sensus Healthcare Analyst Ratings
Maxim Group Maintains Buy on Sensus Healthcare, Raises Price Target to $10
Sensus Healthcare: Strong Q4 Performance and Promising Future Drive Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: Foghorn Therapeutics (FHTX), Sensus Healthcare (SRTS)
Analysts' Top Healthcare Picks: Sensus Healthcare (SRTS), Inotiv (NOTV)
Buy Rating Affirmed for Sensus Healthcare Amidst Strong Performance and Growth Prospects
Analysts Offer Insights on Healthcare Companies: Sensus Healthcare (SRTS), Outlook Therapeutics (OTLK) and Leap Therapeutics (LPTX)
HC Wainwright & Co. Reiterates Buy on Sensus Healthcare, Maintains $8 Price Target